Browse the evidence

GLP-1 receptor agonists (GLP-1RAs) are perceived by patients as effective for weight loss and appetite reduction, with positive treatment experiences correlating with therapy duration of 6 months or longer.

If you are considering GLP-1 medication, know that most patients report significant benefits for weight and appetite, especially if they stay on it for at least 6 months. Be prepared to discuss insurance coverage and side effects openly with your doctor to overcome common barriers.

Integrative Korean Medicine Treatment (IKMT), comprising personalized herbal medicine (including Ephedrae Herba) and dietitian-led lifestyle modification, produces statistically significant weight loss and blood pressure reductions in obese adults with a safety profile comparable to or better than GLP-1 receptor agonists.

This study suggests that a structured program combining personalized herbal medicine (specifically containing Ephedrae Herba) with professional dietary coaching can lead to significant weight loss (average ~8.7%, up to ~28% in best responders) and improved blood pressure. It serves as a viable alternative for individuals who cannot tolerate or afford GLP-1 medications, provided they undergo proper medical screening for contraindications like heart or liver disease.

GLP-1 receptor agonists used for weight management are associated with nutritional deficiencies, specifically protein deficiency and metabolic acidosis, which may lead to malnutrition.

When using GLP-1 medications for weight loss, pay attention to your nutrition. Reports suggest a higher risk of protein deficiency and metabolic acidosis. Ensure you are eating enough protein and staying hydrated. If you feel unwell, dizzy, or experience unusual symptoms, talk to your doctor about your diet and medication.

48 weeks of tirzepatide treatment significantly improves liver steatosis, liver enzymes, and surrogate markers of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM).

For patients with both fatty liver disease and type 2 diabetes, tirzepatide is a well-tolerated treatment that significantly reduces liver fat, improves liver enzyme levels, and slows down fibrosis markers over 48 weeks. While gastrointestinal side effects like nausea are common, they are typically mild and do not force most patients to stop the medication. The benefits extend beyond just weight loss, likely due to the specific dual-action mechanism of the drug on liver metabolism.

Lanifibranor (800-1200 mg daily) significantly improves MASH resolution and fibrosis regression in patients with noncirrhotic MASH compared to placebo.

Lanifibranor (800-1200mg daily) is a promising late-stage drug for MASH that targets multiple metabolic pathways. It significantly improves liver health scores compared to placebo, though monitor for mild weight gain and GI issues.

Saroglitazar (4 mg daily) significantly improves liver enzymes and liver fat content in patients with MASLD/MASH.

Saroglitazar (4mg daily) is approved in India for MASH. It significantly lowers liver enzymes and liver fat. It is currently in Phase 2b trials in the US and other regions.

Tirzepatide therapy significantly improves metabolic control (HbA1c, fasting glucose) and lipid profiles (LDL, HDL, triglycerides) in patients with heart failure.

If you have heart failure and are prescribed tirzepatide, you may see significant improvements in your blood sugar control and lipid profile within six months. This includes lower HbA1c, LDL cholesterol, and triglycerides, and higher HDL cholesterol. These improvements contribute to better long-term cardiovascular health. Discuss these potential benefits with your healthcare provider.

Higher adherence to sports nutrition guidelines, measured by the Athlete Diet Index (ADI), is associated with lower fat mass in professional athletes.

For professional athletes, eating according to sports nutrition guidelines (high ADI score) is linked to having the lowest body fat. For non-professionals, this link is weaker. If you are serious about body composition, aligning your diet with established sports nutrition standards is a key lever, especially if you have access to professional guidance.

Oral supplementation with a specific ratio of three amino acids (3 Glycine : 1 Proline : 1 Hydroxyproline), combined with Vitamin C, astaxanthin, and alpha-ketoglutarate, reduces biological age by approximately 1.4 years in humans over a 6-month period and improves skin texture, hydration, and elasticity within 1-3 months.

Take a daily supplement containing a 3:1:1 ratio of Glycine, Proline, and Hydroxyproline, combined with Vitamin C, Astaxanthin, and Alpha-Ketoglutarate. This specific combination was shown to improve skin texture, hydration, and elasticity within 1-3 months, and reduce biological age by about 1.4 years over 6 months in a clinical trial. It is generally safe, though a small percentage of users may experience mild side effects like rosacea or intestinal reactions.

Household food insecurity is independently associated with higher odds of low muscle mass in U.S. adults, with lower total protein intake acting as a significant partial mediator of this association.

If you are experiencing food insecurity, prioritize protein intake as much as possible, as it is a key factor in maintaining muscle mass. While you cannot control food availability, focusing on protein-rich foods within your budget may help mitigate muscle loss.

Moderate (~10%) weight loss achieved through diet and exercise reduces pro-inflammatory M1-like macrophages in abdominal subcutaneous adipose tissue (SAT) in adults with adult-onset obesity (AO), but fails to alter these immune cell profiles in those with childhood-onset obesity (CO).

If you developed obesity as an adult, moderate weight loss (around 10%) through diet and exercise may help reduce inflammation in your abdominal fat. However, if you have been obese since childhood, the same level of weight loss might not change the inflammatory state of your fat tissue, even if you lose weight and improve blood markers like insulin. This suggests that long-term obesity history creates a 'memory' in fat tissue that is harder to reverse with standard lifestyle changes alone.

Moderate weight loss increases CD3+CD4+ T cells in both abdominal and femoral subcutaneous adipose tissue in adults with adult-onset obesity (AO), but not in those with childhood-onset obesity (CO).

If you developed obesity as an adult, moderate weight loss may trigger an increase in CD4+ T cells in your fat tissue, which could include regulatory T cells that help manage inflammation. If you have been obese since childhood, this specific immune shift may not occur with the same degree of weight loss. This highlights that long-term obesity history creates a 'memory' in fat tissue that is harder to reverse with standard lifestyle changes alone.

Moderate (~10%) weight loss improves systemic cardiometabolic risk factors (plasma insulin and arterial stiffness) similarly in both childhood-onset (CO) and adult-onset obesity (AO) populations.

Losing about 10% of your body weight through diet and exercise significantly improves your blood vessel health (arterial stiffness) and insulin sensitivity, regardless of whether you became obese as a child or as an adult. This is a robust benefit of weight loss that applies to everyone with obesity.

Post-operative nutritional counseling has a lasting 'eye-opening' effect on patient habits, reducing the perceived need for further nutritional education compared to other support areas.

Take the initial nutritional counseling before your surgery seriously. For most patients, this 'eye-opening' session provides enough knowledge to manage diet long-term without needing constant follow-up. Focus your energy on the physical activity aspect, where ongoing support is more critical.

Dietary interventions that modulate gut microbiota composition (specifically increasing SCFA-producing bacteria and reducing dysbiosis) improve metabolic health outcomes including insulin sensitivity and glucose tolerance.

To improve your metabolic health, focus on dietary patterns that support a diverse gut microbiome. This means consuming a variety of plant fibers (prebiotics) to encourage the growth of beneficial bacteria that produce short-chain fatty acids (SCFAs). These SCFAs help regulate blood sugar and insulin sensitivity. Avoid highly processed foods that can cause dysbiosis (microbial imbalance) and inflammation.

High-fat diets induce gut barrier defects and metabolic endotoxemia (elevated LPS), which triggers low-grade inflammation and compromises insulin sensitivity.

Reducing chronic high-fat intake can help maintain gut barrier integrity, preventing the leakage of inflammatory bacterial components (LPS) into the bloodstream, which may improve insulin sensitivity.

High polygenic risk for obesity interacts with specific nutrient intakes (particularly saturated fat and trans fat) to accentuate BMI increases, whereas omega-3 intake may attenuate this genetic susceptibility.

If you have a high genetic risk for obesity, the quality of fat you eat matters more than you might think. Prioritize omega-3 fatty acids and minimize trans fats and saturated fats, as these nutrients can significantly blunt the BMI-increasing effects of your genetic predisposition. Total fat quantity alone is less predictive than fat type.

A clinical decision support system (CDSS) that integrates patient-centered pre-visit questionnaires with provider alerts significantly increases primary care practitioners' self-reported frequency of counseling on behavioral interventions, referring to weight-loss programs, and discussing anti-obesity medications.

For primary care providers, using a clinical decision support system that allows patients to complete a pre-visit questionnaire about their weight management interest can significantly increase the likelihood of you counseling on behavioral changes, referring patients to weight-loss programs, and discussing anti-obesity medications. This approach works by reducing the friction of initiating these conversations and integrating seamlessly into your electronic health record workflow.

High-volume static stretching (≥15 minutes per muscle group, >3 times per week) induces muscle hypertrophy and strength increases comparable to resistance training, primarily by generating high-magnitude mechanical tension that activates mTOR/p70S6K signaling pathways.

If you cannot lift weights due to injury, age, or lack of equipment, perform static stretches for at least 15 minutes per muscle group, 3 or more times a week. Push to the point of discomfort (but not sharp pain). This can build muscle and strength similarly to weightlifting, though it takes longer per session. It is particularly useful for immobilized patients or as a supplement to your regular workouts.

High-volume static stretching improves glycemic control (post-prandial glucose and HbA1c) in individuals with Type 2 Diabetes, potentially by increasing GLUT-4 translocation via AMPK and CaMK pathways.

If you have Type 2 Diabetes, incorporating static stretching into your routine may help lower blood sugar levels, especially after meals. It works by helping your muscles take up glucose without needing as much insulin. It is not a replacement for medication but a helpful addition.

Training with 4-6 or 1-3 repetitions in reserve (RIR) yields comparable strength gains, whereas training to momentary failure (0 RIR) or near-failure (0-3 RIR) results in slightly inferior strength outcomes in trained men.

For strength gains, you do not need to train to failure. Stopping sets with 1-3 reps left in the tank (RIR) produces similar or better strength results than going to failure. Training to failure may actually hinder strength progress due to excessive fatigue and reduced recovery capacity. Focus on maintaining bar speed and consistency rather than absolute exhaustion.

Weight-neutral nutrition and exercise counseling can improve insulin sensitivity in patients with stage 1 obesity, as measured by the Quantitative Insulin Sensitivity Check Index (QUICKI).

If you have stage 1 obesity and metabolic issues, try focusing on improving diet quality (more fiber, less sodium, healthy fats) and increasing physical activity without stressing about the number on the scale. This approach can improve your insulin sensitivity for some people, even if you don't lose weight.

Metformin augmentation for non-responders to initial behavioral interventions provides a potential rescue effect but is associated with gastrointestinal side effects that challenge adherence.

If behavioral changes alone don't improve your insulin sensitivity, adding metformin might help, but be prepared for potential stomach issues. Starting with a low dose and using extended-release versions can help manage side effects.

Psychological distress (stress, anxiety, depression) and environmental barriers (food insecurity, poor neighborhood quality) significantly increase the risk of weight regain after intentional weight loss by driving disinhibited eating and reducing behavioral adherence.

If you are struggling to maintain weight loss, look beyond just calories. Assess your stress levels, mental health, and your physical environment (food access, neighborhood safety). High stress and poor food environments are proven drivers of weight regain. Addressing these external and psychological factors is essential for long-term success, not just willpower.